Viral Infections Vaccines & Prevention Public Health

Hepatitis C elimination a 'political commitment challenge'

Share

Objective:

To review progress toward hepatitis C elimination, gaps in prevention and treatment, strategies for reaching populations facing care barriers, and investigational prevention and treatment approaches.

Approach:
  • : Ward reviewed global estimates, national programs, priority populations and barriers involving prevention services, financing and confirmatory testing costs.
  • : Terrault discussed U.S. care gaps, Veterans Affairs initiatives, hospital-based treatment and emergency-department screening.
  • : Trooskin addressed integrated care for populations facing barriers. Thomas reviewed vaccine research and a potential single-injection treatment.
Key Findings:
  • Ward cited approximately 47 million people with hepatitis C worldwide, about 20% fewer than in 2015. Incidence declined about 8% and deaths about 12%, below the respective 2030 reduction goals of 90% and 65%.
  • Egypt reduced prevalence from 10% to 0.4%. England reported declines of 61% in general-population prevalence and 18% in mortality during 2015-2024. Spain reported declines of 40% in general-population prevalence, 53% in mortality and 92% in prevalence among incarcerated people during 2015-2023.
  • Terrault reported that approximately 68% of U.S. patients had been diagnosed and 43% of diagnosed patients had received treatment, compared with targets of 90% and 80%.
  • In OPPORTUNI-C, treatment initiation within six months reached 85.7% with hospital-based assessment and treatment or rapid post-discharge care, versus 46.1% with usual outpatient referral.
  • In DETECT Hep C, nontargeted emergency-department screening produced a 34% higher diagnosis rate than targeted screening, but substantial losses occurred before linkage to care.
  • In HERO, per-protocol sustained virologic response rates exceeded 90%; intention-to-treat rates were lower. A separate analysis found response rates above 90% with medication adherence as low as 50%. Trooskin encouraged completing all prescribed medication.
  • Montreal modeling projected that prison-based testing and treatment could reduce incidence by 48% and prevent 22% of new chronic infections; adding risk reduction increased the projected proportion prevented to 35%.
  • A vaccine trial generated immune responses but did not reduce progression to chronic infection. Injectable glecaprevir/pibrentasvir showed prolonged drug exposure in rats, with human testing planned for 2027.
Interpretation:

Ward characterized elimination as increasingly a political commitment challenge. Speakers emphasized financing, prevention, integration into existing services and focused efforts in populations facing care barriers.

Limitations:
  • The article summarizes selected findings without complete study methods or confidence intervals.
  • Global figures include estimates, and the Montreal findings are projections.
  • HERO results differed by analysis population; injectable treatment findings were preclinical.
Conclusion:

Hepatitis C elimination requires expanded prevention, diagnosis and curative treatment, supported by financing and integrated care. Vaccine development and single-injection treatment remain investigational.

Sources: